BIOPHARMA SIGNAL

Pharma Weekly Times

16 Nov 2026 – 22 Nov 2026

PARTNERSHIP / MIDDLE EAST & AFRICA

IP

Arcera and Innogen announce a multi-region licensing deal

Arcera announced exclusive licensing and commercialisation rights in selected markets including the UAE, with upfront, milestone and royalty components for Innogen.

Arcera Life Sciences 19 Nov 2026

DIGITALISATION / EUROPE

Isomorphic Labs announces MSD discovery collaboration

Isomorphic Labs announced a research collaboration with MSD in oncology drug discovery.

Isomorphic Labs 19 Nov 2026

CAPACITY EXPANSION / CHINA

Roche marks construction completion for Shanghai biopharma base

Shanghai's municipal government reported that Roche's chair was in the city for a ceremony marking construction completion of its biopharmaceutical production base.

Shanghai Municipal Government 19 Nov 2026

PARTNERSHIP / CHINA

ST

Suzhou-based Starna announces Pfizer licensing deal

Starna announced a licensing agreement granting Pfizer rights outside Greater China to three early-stage programmes. Pfizer disclosed a $330 million upfront payment and up to $2.3 billion in contingent milestones.

Starna Therapeutics 19 Nov 2026

CELL & GENE THERAPY / EUROPE

MHRA

UK confirms plans to update the gene therapy definition

The UK government confirmed plans to modernise the legal definition of gene therapy medicinal products following consultation.

UK MHRA 19 Nov 2026

REGULATION / CHINA

NHSA

China announces regional rollout to support access to newly listed medicines

The NHSA announced outreach in 12 provincial-level jurisdictions from 21 November to inform clinicians, insurers and pharmacies about newly listed medicines.

National Healthcare Security Administration 18 Nov 2026

PARTNERSHIP / EUROPE

VERT

Genomics and Vertex extend discovery partnership

Genomics announced a four-year extension with Vertex. Potential milestone-linked contract value exceeds $220 million, with tiered royalties also described.

Genomics Ltd. 18 Nov 2026

REGULATION / CHINA

HARBOUR BIOMED

Harbour BioMed reports China acceptance of LET003 filing

Harbour BioMed said China's NMPA accepted the investigational new drug application for LET003, which the company describes as its first AI-enabled drug candidate.

Harbour BioMed 18 Nov 2026